Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Annette Hasenburg Prof., Dr, med

Annette Hasenburg Prof., Dr, med

Director, Obstetrics and Gynecology, Mainz University Medical Center, Mainz, Germany

Dr. Annette Hasenburg is the Director of Obstetrics and Gynecology at Mainz University Medical Center in Mainz, Germany. She is Head of the ESGO (European Society of Gynaecologic Oncology) Task Force Psycho-Oncology and is on the board of directors of the Institute of Sexuality and Health of the University Freiburg in Freiburg, Germany.

Dr. Hasenburg received her medical degree from Ruhr-University, Bochum, Germany, where she also received residency training in internal medicine (Evangelisches Krankenhaus Herne) and obstetrics and gynecology (Marienhospital Herne). She received specialist training and qualification in psychotherapy at the Institute of Psychotherapy and Psychosomatic Medicine in Düsseldorf. She completed a postdoctoral fellowship in the Department of Obstetrics and Gynecology, Oncology Division, at Baylor College of Medicine in Houston, Texas.

Since 2018, Dr. Hasenburg has been on the Board of Directors of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie) and since 2020 on the Board of Directors of the DGGG (Deutsche Gesellschaft Gynäkologie und Geburtshilfe).

Disclosures

  • Honoraria: AstraZeneca; Celgen; GSK; LEO Pharma; MedConcept GmbH; Med update GmbH; Medicultus; Pfizer; Promedicis GmbH; Softconsult; Roche Pharma AG; Streamedup! GmbH; Tesaro Bio Germany GmbH
  • Advisory roles: AstraZeneca; GSK; LEO Pharma; PharmaMar; Promedicis GmbH; Roche Pharma AG; Tesaro Bio Germany GmbH; MSD (Merck Sharp & Dohme) GmbH

Recent Contributions to PracticeUpdate:

  1. Surgical Techniques and Their Impact on Sexuality and Quality of Life Among Ovarian Cancer Patients
  2. Key Takeaways From ESMO: Updates on Ovarian Cancer
  3. Key Takeaways From ESMO: Updates on Cervical and Endometrial Cancer
  4. ESMO 2020: Recommendations From Dr. Annette Hasenburg for Gynecologic Cancer
  5. Impact of Molecular Classification on Prognosis and Benefit From Adjuvant Therapy for High-Risk Endometrial Cancer
  6. Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy
  7. ASCO: Safety of Sentinel Lymph Node Biopsy in Early-Stage Cervical Cancer
  8. ASCO: Final Overall Survival Results for Olaparib Maintenance in BRCA-Mutated Ovarian Cancer
  9. ASCO: Pembrolizumab for Recurrent Ovarian Cancer
  10. ASCO: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer

Elsewhere

Most Read This Week

Recently Updated